Publications by authors named "A Zaniboni"
Perioperative safety and oncological efficacy of simultaneous versus colorectal and liver first two-staged resections in patients with synchronous colorectal liver metastases: a systematic review and network meta-analysis.
HPB (Oxford)
November 2024
Background: Previous meta-analyses have yielded conflicting results on the optimal surgical treatment strategy in patients with synchronous colorectal liver metastases (sCRLM). This network meta-analysis aims to provide an overview on colorectal-, liver first and simultaneous resections to treat sCRLM.
Methods: A search was conducted in MEDLINE, Embase and Cochrane CENTRAL (inception-July 11,2023).
Purpose: KRASG12D mutation (mut) occurs in about 10%-12% of metastatic colorectal cancer (mCRC). Recently, novel KRASG12D inhibitors have been developed and are currently under investigation in phase I/II clinical trials in solid tumors including mCRC. We aimed at performing a comprehensive characterization of clinical, molecular, immunologic, and prognostic features of KRASG12D-mutated mCRC to inform the design and the interpretation of future trials.
View Article and Find Full Text PDFArticle Synopsis
- Ascites is a common issue in patients with advanced gastrointestinal cancers that have spread to the peritoneum, impacting survival negatively; this study is the first to look specifically at ascites, peritoneal metastases (PM), and survival in metastatic colorectal cancer (mCRC) and metastatic gastric cancer (mGC).
- A retrospective analysis of clinical trial data showed that mCRC patients with ascites had significantly shorter progression-free and overall survival compared to those without PM, while gastric cancer patients with ascites also had poorer survival outcomes and higher disease severity scores.
- The findings suggest that ascites can indicate worse prognoses for certain cancer patients, highlighting the need for more focused research and tailored treatments for these individuals.
Article Synopsis
- - First-line combo treatments using CDK4/6 inhibitors with endocrine therapy have improved outcomes for advanced hormone receptor positive (HR+)/HER2- breast cancer, but resistance can develop over time.
- - ESR1 gene mutations contribute to resistance against aromatase inhibitors, which may inform the use of therapies like fulvestrant or new oral selective estrogen receptor degraders (SERDs).
- - New targeted treatments, such as PARP inhibitors for BRCA mutations and antibody-drug conjugates like trastuzumab deruxtecan, highlight the importance of personalized approaches and early intervention based on specific genetic changes in metastatic breast cancer.
The incidence of biliary tract cancer is increasing in developed countries and is generating renewed interest in the scientific community due to the evidence of a high percentage (approximately 40%) of potentially targetable molecular alterations. However, to date, patient selection and the development of therapeutic approaches remain challenging due to the need for accurate diagnosis, adequate sampling, a specialized team for molecular analysis, centralization of patients in high-volume centers capable of supporting the high cost of these methods, and the feasibility of clinical studies on diseases with aggressive onset and poor prognosis. In this article, we would like to provide a detailed overview of the necessary tools for diagnostic framing and the various therapeutic scenarios being investigated concerning the most frequently detected molecular alterations.
View Article and Find Full Text PDF